SCHEMBL3729360

SCHEMBL3729360

CC(N)(CO)CCc1ccc2oc(-c3ccc(O)cc3)nc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 7/20 0.54
ESR2 Q92731 7/20 0.54
NPC1 O15118 8/20 0.50
RAB9A P51151 8/20 0.50
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MEN1 O00255 2/20 0.50
MAPT P10636 2/20 0.50
KMT2A Q03164 2/20 0.50
TP53 P04637 2/20 0.50
HSD17B10 Q99714 2/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
PIK3CA P42336 1/20 0.45
PIK3CB P42338 1/20 0.45
GFER P55789 2/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3729358 1.00 ESR1 (0.54) ESR1ESR2NPC1RAB9AKDM4E
SCHEMBL3731794 0.90 NPC1 (0.49) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL3731795 0.90 NPC1 (0.49) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL3731120 0.90 SMN1; SMN2 (0.50) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL3731114 0.90 SMN1; SMN2 (0.50) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL3727000 0.88 HDAC3 (0.49) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL3726997 0.88 HDAC3 (0.49) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL3731478 0.85 KDM4E (0.45) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL3731473 0.85 KDM4E (0.45) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL3729192 0.84 MAPT (0.47) NPC1RAB9AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1622866-B1 AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS NOVARTIS AG (CH) 2012-07-25 EP disclosed
US-7825260-B2 Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators NOVARTIS AG (CH) 2010-11-02 US disclosed
US-20060211656-A1 Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators NOVARTIS AG (CH) 2006-09-21 US disclosed
EP-1622866-A1 AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS Novartis AG (CH) 2006-02-08 EP disclosed
WO-2004096757-A1 AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS NOVARTIS AG (CH) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211656-A1 Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators S1PR1, S1PR3, S1PR2 ESR1 989/4885ESR2 472/4885NPC1 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.